title: Dose-related stimulatory effect of clarithromycin on interdigestive gastroduodenal motility.
abstract: OBJECTIVE
  The effect on interdigestive gastroduodenal motility of different doses of clarithromycin, an antibiotic commonly used for Helicobacter pylori eradication, has been investigated.
  
  
  METHODS
  Gastroduodenal motility was recorded by means of a low-compliance manometric system in 15 healthy subjects. Thirty minutes after the first phase III of the migrating motor complex, clarithromycin (CLA) was infused intravenously at a dose of 100 mg in 5, 250 mg in 5 and 400 mg in 5 subjects, randomly and in a double-blind manner, continuing the recording for at least 1 h. A further study was carried out on 10 subjects, 5 of whom received 50 mg CLA and 5 normal saline with the same modalities.
  
  
  RESULTS
  After 100 mg CLA a premature gastroduodenal phase III ensued in all cases, which showed a duration, propagation velocity and wave frequency not significantly different from the spontaneous one and was followed by a clear phase I. A premature gastroduodenal phase-III-like activity occurred in 3 cases of 250 mg CLA and 2 cases after 400 mg CLA, followed by a very short or absent phase I and characterized by a long duration of the antral phase III, while in the remaining cases a long-lasting sequence of about 1/min of antral waves propagated to the duodenum appeared, sometimes preceded by an antral phase-III-like activity not propagated to the duodenum. After 50 mg CLA a premature phase III appeared in 2 cases, while a not premature phase III appeared in 2 cases after saline.
  
  
  CONCLUSIONS
  CLA shows a dose-related stimulatory effect on interdigestive gastroduodenal motility varying from the initiation of a typical phase III to a prolonged sequence of gastroduodenal coordinated waves. These motor effects of CLA suggest potential therapeutic applications.
authors.affiliation: Department of Internal Medicine and Gastroenterology, University of Bologna, Italy. bortolottim@orsola-malpighi.med.unibo.it
authors.forename: M
authors.initials: M
authors.lastname: Bortolotti
authors.forename: V
authors.initials: V
authors.lastname: Annese
authors.forename: C
authors.initials: C
authors.lastname: Mari
authors.forename: C
authors.initials: C
authors.lastname: Lopilato
authors.forename: G
authors.initials: G
authors.lastname: Porrazzo
authors.forename: M
authors.initials: M
authors.lastname: Miglioli
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017291:Clarithromycin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004386:Duodenum / Q000187:drug effects / Q000502:physiology; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D016481:Helicobacter Infections / Q000188:drug therapy; D006801:Humans; D008297:Male; D008365:Manometry; D008875:Middle Aged
chemical_list: D000900:Anti-Bacterial Agents; D017291:Clarithromycin